Diagnostic and prognostic value of the methylation status of secreted frizzledrelated protein 2 in colorectal cancer

Clinical and Investigative Medicine

Volumn 34, Issue 2, 2011, Pages

  Tang, Dong ^a   Liu, Jun ^a   Wang, Dao Rong ^a   Yu, Hai Feng ^a   Li, Yong Kun ^a   Zhang, Jing Qiu ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FRIZZLED PROTEIN;

ARTICLE; COLORECTAL TUMOR; DNA METHYLATION; HUMAN; METABOLISM; POLYMERASE CHAIN REACTION; PROGNOSIS;

COLORECTAL NEOPLASMS; DNA METHYLATION; FRIZZLED RECEPTORS; HUMANS; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 79960914809     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Ferlay J, Autier P, Boniol M. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
3. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002; 3: 101-128.
4. Jass JR, Young J, Leggett BA. Evolution of colorectal cancer: change of pace and change of direction. J Gastroenterol Hepatol 2002; 17:17-26.
5. Cappell MS. From colonic polyps to colon cancer: pathophysiology, clinical presentation, screening and colonoscopic therapy. Minerva Gastroenterol Dietol 2007; 53: 351-373.
6. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-560.
7. Imperiale TF, RansohoffDF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N EnglJ Med 2004; 351: 2704-2714.
8. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful ? Clin Chem 2001; 47: 624-630.
9. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and Hemo Quant tests. JAMA 1993; 269: 1262-1267.
10. GreenbergPD, Bertario L, GnauckR, et al. A prospective multi-center evaluation of new fecal occult blood tests in patients un dergoing colonoscopy. Am J Gastroenterol 2000; 95: 1331-338.
11. Lee CK, Lee JH, Lee MG, et al. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorec tal tumors. BMC Cancer 2010;10:577.
12. Satelli A, Rao US. Galectin-1 is silenced bypromoter hyper methylation and its re-expression induces apoptosis in human colorectal cancer cells. Cancer Lett 2011;301:38-46.
13. van der Drift MA, Hoi BE, Klaassen CH, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 2010;68:283-287.
14. Czeiger D, Shaked G, Eini H, et al. Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. Am J Clin Pathol 2011;135:264-270.
15. Leung WK, To KF, Man EP. Quantitative detection of promoter hypermethylation in multiple genes inthe serum of patients with colorectal cancer. Am J Gastroenterol 2005; 100: 2274-2279.
16. Lenhard K, Bommer GT, Asutay S. Analysis of promoter methy lation in stool: an ovel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 142-149.
17. Muller HM, Oberwalder M, Fiegl H. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363:1283-1285.
18. Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 2002; 24: 811-820.
19. Uren A, Reichsman F, Anest V, et al. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J Biol Chem 2000; 275: 4374-4382.
20. Su HY, Lai HC, Lin W, et al. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Can cer 2009; 124: 387-393.
21. Suzuki H, Toyota M, Carraway H, et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Can cer 2008; 98: 1147-1156.
22. Nojima M, Suzuki H, Toyota M, et al. Frequent epigenetic inac tivation of SFRP genes and constitutive activation of Wnt signal ing in gastric cancer. Oncogene 2007; 26: 4699-4713.
23. Takagi H, Sasaki S, Suzuki H, et al. Frequent epigenetic inactiva tion of SFRP genes in hepatocellular carcinoma. J Gastroenterol 2008; 43: 378-389.
24. Huang ZH, Li LH, Yang F. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol 2007; 13: 950-954.
25. Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 2008; 14: 524-531.
26. Imperiale TF, Sox HC. Guidelines for surveillance intervals after polypectomy: coping with the evidence. Ann Intern Med 2008; 148:477-479.
27. Cheng YY, Yu J, Wong YP, et al. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 2007;97:895-901.
28. Belshaw NJ, Elliott GO, Foxall RJ, et al. Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer 2008; 99: 136-142.
29. Laird PW The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266.
30. Cottrell SE. Molecular diagnostic applications of DNA methyla tion technology. Clin Biochem 2004; 37: 595-604.
31. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665.